Diana Tran

Thailand cannabis legalization

Aug 30, 2021 | Blogs | 0 comments

5th August 2021

Read time: 2 minutes

Thailand has become the first southeast Asian country to legalize cannabis for medical use. Cannabis was originally introduced into Thailand from India, and until it was outlawed in the 1930s, it was historically used as a kitchen condiment, medicine and source of fiber.

The law legalizing medical marijuana essentially excludes all foreign companies, as well as foreign majority companies incorporated in Thailand, from producing, selling, importing, exporting and processing cannabis as well as other exclusions. This move has been viewed as an effort to protect local companies from an onslaught of highly capitalized foreign entities. The Narcotics Act of 2019 is a modification of the Narcotics Act of 1979. While the recreational use of the substance remains illegal, Thai citizens can now apply for cannabis treatment for 1 or more of 38 registered medical conditions.

The Thailand cannabis bloom

Hemp is known for its strong fiber, which can be made into rope, paper, clothing and other products, and parts of the hemp plant can be processed to make medicine, food and cosmetics. Thai households can now grow up to six pots of cannabis, helping to supply crop to public hospitals and state facilities, or use them to make food and cosmetics to supplement income.

Although hemp and cannabis are in the same family, Thai regulatory authorities differentiate between them because hemp is nearly THC-free (must be under at least 0.2% by weight).7 This difference in potency will be the focus of medical cannabis testing regulations, which are still in the works, to distinguish hemp from marijuana, given that they are essentially the same plant chemically.

Thailand is a budding cannabis market that includes both hemp and marijuana. The market value of cannabis in Thailand is estimated to be between US$660 million and US$2.5 billion by 2024.4 All eyes are on the global legalization of marijuana, and with the varied regulations in the US compared to the uniform federal regulations in Canada, it will be interesting to see if Thailand follows either of these approaches in terms of recreational use and testing standards.

DISCLAIMER: THIS IS NOT INTENDED TO PROVIDE LEGAL ADVICE

References

1. New Announcement Of Cannabis Legalization In Thailand-February 8 2021 Herrera & Partners

2. CANNABIS CATALYSTS- https://www.cannabiscatalysts.com/medical-cannabis-legalization-in-thailand

3. Cannabis for Thailand – https://cannabisforthailand.com/thailand-medical-cannabis/

4. EASTASIAFORUM – https://www.eastasiaforum.org/2021/05/13/can-medical-cannabis-in-thailand-balance-profits-and-patients/ 5. Healthline – https://www.healthline.com/health/hemp-vs-marijuana#marijuana 6. Bloomberg – https://www.bloomberg.com/news/articles/2021-03-05/thai-families-can-grow-six-pots-of-cannabis-each-as-rules-eased 7. HempToday – https://hemptoday.net/thailand-sets-strict-rules-for-cosmetics-hemp-under-3-year-govt-monopoly/

RUO-MKT-18-13469

Is “right first time, every time” a pipedream for metabolite identification by LC-MS?

If we lived in an ideal world, it would be possible to unambiguously identify metabolites using a single analytical experiment. This analytical technique would need to be efficient and easily generate the information needed from a routine assay that is also robust, enabling confident decision-making during drug discovery.

Supporting new CRISPR gene editing systems

Prime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).

A new approach for comprehensive AAV evaluation including full and empty analysis

Certain next-gen vaccines and gene therapy applications rely on the usage of adeno-associated viruses (AAV) as a delivery vehicle. To ensure the safety and efficacy of viral vector drugs, multiple critical quality attributes (CQAs) need to be well characterized.

Posted by

Diana Tran

Senior Applications Scientist, SCIEX. Diana Tran specializes in LC-MS/MS method development as an applications scientist at SCIEX. For the past 4 years, she has been actively involved in cannabis testing analysis and has had a hand in almost every cannabis method developed at SCIEX since then. Diana has been field tested in testing labs across the US, making connections in cannabis testing labs and acting as a resource for analytical chemists. She is always looking for new cannabuds—feel free to reach out and start a conversation.

0 Comments